Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS1033 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Single Ascending Dose (SAD) | EXPERIMENTAL | Participants will receive single ascending dose (SAD) of INS1033 or a matching placebo orally under fasted conditions on Day 1. |
| Part 2: Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants will receive multiple ascending dose (MAD) of INS1033 or a matching placebo orally under fasted conditions for up to 14 days. |
| Name | Type | Description |
|---|---|---|
| INS1033 | DRUG | Oral solution |
| Placebo | DRUG | Oral solution |
Inclusion Criteria: * Healthy status as defined by the absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead electrocardiogram...
INS1033 is an investigational small molecule being developed by Insmed Incorporated. It is in Phase 1 clinical development, with a single active trial currently recruiting healthy adult volunteers in the United States. No therapeutic indication for INS1033 has been disclosed.
INS1033 is being developed by Insmed Incorporated, which trades on the Nasdaq under the ticker INSM. Insmed is the sponsor of the Phase 1 study evaluating the compound in healthy participants.
INS1033 is in Phase 1 clinical development. It has one active, recruiting trial and no completed trials. Because it is investigational, INS1033 has not been approved by the FDA for any indication.
INS1033 is being studied in one Phase 1 trial, NCT07765706, titled a study to assess the safety, tolerability and pharmacokinetics of INS1033 in healthy participants. The trial is recruiting, is randomized, double blind, and controlled, and plans to enroll 116 healthy volunteers aged 18 and older in the United States.
Yes. The Phase 1 trial of INS1033, NCT07765706, enrolls healthy adult volunteers rather than patients with a specific disease. The study is designed to assess safety, tolerability, and pharmacokinetics, and it plans to enroll 116 participants across sites in the United States.